查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1572042

抗血栓藥物市場：按藥物類別、給藥途徑、應用、最終用戶、年齡層分類 - 全球預測 2025-2030

Antithrombotic Drugs Market by Drug Class (Antiplatelet Agents, Direct Thrombin Inhibitors, Factor Xa Inhibitors), Route of Administration (Injectable, Oral), Application, End User, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗血栓藥物市值為400.8億美元，預計2024年將達到424.7億美元，複合年成長率為6.04%，到2030年將達到604.5億美元。

抗血栓藥物市場包括多種旨在預防血栓症的產品，包括抗凝血劑、抗血小板劑和血栓溶解劑。這些藥物對於深層靜脈栓塞症、肺動脈栓塞、心肌梗塞和中風等疾病的管理和預防至關重要，是心血管疾病管理的基石。全球心血管疾病、肥胖和久坐生活方式的發病率不斷增加，推動了對此類藥物的需求。應用範圍涵蓋醫院、門診手術中心和居家醫療，最終用戶包括醫療保健提供者和患者。關鍵的成長要素包括更容易患血栓性疾病的人口老化以及導致更有效藥物配方開發的技術進步。此外，越來越多的人患有與文明病，這產生了對預防性醫療措施的需求，這為正在開發醫療基礎設施的新興市場創造了潛在的成長機會。然而，市場面臨藥物開發高成本、監管挑戰以及長期抗凝血治療副作用導致的依從性問題等限制。複雜的監管環境和嚴重藥物交互作用的風險進一步阻礙了成長。創新技術和研究領域正在開拓，包括開發新型口服抗凝血劑（NOAC），以提供更好的安全性並減少監測需求。此外，個人化醫療利用基因檢測為個別患者量身定做治療方案，是實現差異化和市場滲透的一條有前途的途徑。由於激烈的市場競爭和快速的技術創新，主要企業正專注於策略聯盟、合併和研究合作，以加強其產品組合和地理覆蓋範圍。為了利用這些機會，公司正在投資研發以克服已發現的局限性，同時創造開拓的市場，特別開拓不斷成長的老年人口和不斷上升的血栓性疾病患病率。

主要市場統計
基準年[2023] 400.8億美元
預測年份 [2024] 424.7億美元
預測年份 [2030] 604.5億美元
複合年成長率（%） 6.04%

市場動態：揭示快速發展的抗血栓藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗血栓藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 越來越多的老年人口容易發生血栓事件，需要持續的藥物治療
    • 透過擴大新興國家的醫療基礎設施改善醫療服務
    • 由於醫療成本增加和醫學研究投資促進藥物開發
    • 製藥公司之間的聯盟和夥伴關係推動抗血栓治療的創新
  • 市場限制因素
    • 與抗血栓藥物相關的副作用和安全問題限制了臨床接受度
    • 專利到期和學名藥競爭降低了抗血栓藥物的盈利和市場機會
  • 市場機會
    • 擴大醫療基礎設施以推動抗血栓藥物在新興市場的採用
    • 藥物傳遞系統的技術進步提高了抗血栓藥物的有效性
    • 藥廠與研究機構合作加速抗血栓藥物研發
  • 市場挑戰
    • 解決抗血栓藥物開發和行銷中病患的安全性和有效性問題
    • 應對抗血栓藥物市場中生物技術和個人化醫療的快速發展

波特五力：駕馭抗血栓藥物市場的策略工具

波特的五力框架是了解抗血栓藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗血栓藥物市場的外部影響

外部宏觀環境因素在塑造抗血栓藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗血栓藥物市場競爭狀況

抗血栓藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗血栓藥物市場供應商績效評估

FPNV定位矩陣是評估抗血栓藥物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗血栓藥物市場的成功之路

抗血栓藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 越來越多的老年人口容易發生血栓症，需要持續用藥
      • 擴大新興國家的醫療基礎設施改善醫療服務的可近性
      • 醫療保健成本上升和醫學研究投資推動藥物開發
      • 製藥公司之間的合作與夥伴關係，促進抗血栓治療的創新
    • 抑制因素
      • 與抗血栓藥物相關的副作用和安全問題限制了臨床接受度
      • 專利到期和學名藥競爭，降低了抗血栓藥物的盈利和市場機會。
    • 機會
      • 擴大醫療基礎設施推動新興市場採用抗血栓藥物
      • 藥物傳遞系統的技術進步提高了抗血栓藥物的有效性
      • 製藥公司與研究機構合作加速抗血栓藥物開發
    • 任務
      • 抗血栓藥物在開發和行銷過程中解決了患者的安全性和有效性問題
      • 抗血栓藥物市場與生物技術和個人化醫療的快速發展保持同步
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的抗血栓藥物市場

  • 抗血小板藥
    • 阿斯匹靈
    • Clopidogrel
    • 普拉格雷
  • 直接凝血酶抑制劑
    • Dabigatran
  • Xa因子抑制劑
    • Apixaban
    • 艾多沙班
    • Rivaroxaban
  • 維生素K拮抗劑
    • Warfarin

第7章抗血栓藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章抗血栓藥物市場：依應用分類

  • 急性冠狀動脈症候群
  • 心房顫動
  • 深部靜脈血栓和肺栓塞

第9章抗血栓藥物市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第10章抗血栓藥物市場：依年齡層

  • 成人用
  • 老年病
  • 小兒科

第11章美洲抗血栓藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗血栓藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗血栓藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C01CD

The Antithrombotic Drugs Market was valued at USD 40.08 billion in 2023, expected to reach USD 42.47 billion in 2024, and is projected to grow at a CAGR of 6.04%, to USD 60.45 billion by 2030.

The antithrombotic drugs market encapsulates a wide range of products aimed at preventing thrombosis, including anticoagulants, antiplatelet drugs, and thrombolytic drugs. These medications are crucial in managing and preventing conditions such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke, making them a cornerstone of cardiovascular disease management. The necessity for these drugs is driven by the increasing incidence of cardiovascular disorders, obesity, and sedentary lifestyles globally. Applications span across hospital settings, ambulatory surgical centers, and home care, with end-users including healthcare providers and patients. Key growth influencers include the aging population, which is more susceptible to thrombotic diseases, and ongoing technological advancements leading to the development of more effective drug formulations. Furthermore, an increasing number of individuals with lifestyle diseases calls for preventive healthcare measures, creating potential growth opportunities in emerging markets with rising healthcare infrastructure. However, the market faces limitations such as high costs associated with drug development, regulatory challenges, and adherence issues due to the side effects of long-term anticoagulation therapy. The complex regulatory landscape and risk of significant drug interactions pose additional barriers to growth. Innovations and research areas ripe for exploration include the development of novel oral anticoagulants (NOACs), which offer better safety profiles and reduced monitoring requirements. Furthermore, personalized medicine, leveraging genetic testing to tailor treatments to individual patients, offers a promising avenue for differentiation and market penetration. The market is highly competitive with a nature of rapid innovation, leading pharmaceutical companies to focus on strategic partnerships, mergers, and collaborations to enhance their portfolios and geographic reach. To capitalize on these opportunities, companies should invest in R&D and focus on overcoming the identified limitations while exploring untapped markets, particularly in regions with growing geriatric populations and rising incidences of thrombotic diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 40.08 billion
Estimated Year [2024] USD 42.47 billion
Forecast Year [2030] USD 60.45 billion
CAGR (%) 6.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antithrombotic Drugs Market

The Antithrombotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population susceptible to thrombotic events requiring consistent medication
    • Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
    • Rising healthcare expenditure and investment in medical research boosting drug development
    • Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
  • Market Restraints
    • Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
    • Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
  • Market Opportunities
    • Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
    • Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
    • Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
  • Market Challenges
    • Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
    • Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market

Porter's Five Forces: A Strategic Tool for Navigating the Antithrombotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antithrombotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antithrombotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antithrombotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antithrombotic Drugs Market

A detailed market share analysis in the Antithrombotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antithrombotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antithrombotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antithrombotic Drugs Market

A strategic analysis of the Antithrombotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombotic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alere Inc., Aralez Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Portola Pharmaceuticals, Roche Holding AG, Sanofi S.A., and The Medicines Company.

Market Segmentation & Coverage

This research report categorizes the Antithrombotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antiplatelet Agents, Direct Thrombin Inhibitors, Factor Xa Inhibitors, and Vitamin K Antagonists. The Antiplatelet Agents is further studied across Aspirin, Clopidogrel, and Prasugrel. The Direct Thrombin Inhibitors is further studied across Dabigatran. The Factor Xa Inhibitors is further studied across Apixaban, Edoxaban, and Rivaroxaban. The Vitamin K Antagonists is further studied across Warfarin.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Application, market is studied across Acute Coronary Syndrome, Atrial Fibrillation, and DVT and PE.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population susceptible to thrombotic events requiring consistent medication
      • 5.1.1.2. Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
      • 5.1.1.3. Rising healthcare expenditure and investment in medical research boosting drug development
      • 5.1.1.4. Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
      • 5.1.2.2. Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
      • 5.1.3.2. Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
      • 5.1.3.3. Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
      • 5.1.4.2. Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antithrombotic Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antiplatelet Agents
    • 6.2.1. Aspirin
    • 6.2.2. Clopidogrel
    • 6.2.3. Prasugrel
  • 6.3. Direct Thrombin Inhibitors
    • 6.3.1. Dabigatran
  • 6.4. Factor Xa Inhibitors
    • 6.4.1. Apixaban
    • 6.4.2. Edoxaban
    • 6.4.3. Rivaroxaban
  • 6.5. Vitamin K Antagonists
    • 6.5.1. Warfarin

7. Antithrombotic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Antithrombotic Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Coronary Syndrome
  • 8.3. Atrial Fibrillation
  • 8.4. DVT and PE

9. Antithrombotic Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Clinics
  • 9.4. Hospitals

10. Antithrombotic Drugs Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Antithrombotic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antithrombotic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antithrombotic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTITHROMBOTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTITHROMBOTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PRASUGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DVT AND PE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTI